RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 2	2025-07-15		NCT07065435

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Anhui Provincial Hospital	101
Huai'an First People's Hospital	20
RenJi Hospital	264
Shanghai Minhang Central Hospital	10
The Affiliated Hospital of Xuzhou Medical University	68
The First Affiliated Hospital with Nanjing Medical University	319
The First Hospital of Jilin University	154
Zhejiang Cancer Hospital	142

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Affiliated Hospital with Nanjing Medical University	Nanjing	China	14